Seana Carson - Bausch Health Exec Counsel
| BVF Stock | EUR 7.43 0.08 1.07% |
Insider
Seana Carson is Exec Counsel of Bausch Health Companies
| Age | 51 |
| Phone | 514-744-6792 |
| Web | https://www.bauschhealth.com |
Seana Carson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Seana Carson against Bausch Health stock is an integral part of due diligence when investing in Bausch Health. Seana Carson insider activity provides valuable insight into whether Bausch Health is net buyers or sellers over its current business cycle. Note, Bausch Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bausch Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Seana Carson over two months ago Disposition of 13370 shares by Seana Carson of Bausch Health at 6.21 subject to Rule 16b-3 | ||
Seana Carson over three months ago Disposition of tradable shares by Seana Carson of Bausch Health at 7.61 subject to Rule 16b-3 | ||
Seana Carson over six months ago Disposition of 133 shares by Seana Carson of Bausch Health at 9.8 subject to Rule 16b-3 | ||
Seana Carson over six months ago Acquisition by Seana Carson of 147536 shares of Bausch Health subject to Rule 16b-3 |
Bausch Health Management Efficiency
The company has return on total asset (ROA) of 0.0338 % which means that it generated a profit of $0.0338 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.8761) %, meaning that it generated substantial loss on money invested by shareholders. Bausch Health's management efficiency ratios could be used to measure how well Bausch Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Bernd Sablowsky | Talanx AG | 53 | |
| Norman Fitzgerald | NMI Holdings | 56 | |
| Tomas Duffy | SIVERS SEMICONDUCTORS AB | 62 | |
| Caroline Schlienkamp | Talanx AG | 49 | |
| Christopher Lohmann | Talanx AG | 55 | |
| Mohammad Yousaf | NMI Holdings | 47 | |
| Dag Sigurd | SIVERS SEMICONDUCTORS AB | 73 | |
| Manfred Mueller | Identiv | 53 | |
| Erik Wiklund | SIVERS SEMICONDUCTORS AB | 49 | |
| Leigh Dow | Identiv | N/A | |
| Sven Pettersson | SIVERS SEMICONDUCTORS AB | 60 | |
| FCA FCA | Superior Plus Corp | 68 | |
| Torsten Leue | Talanx AG | 57 | |
| Allison Miller | NMI Holdings | N/A | |
| Amir Khoshniyati | Identiv | N/A | |
| Steven Humphreys | Identiv | 62 | |
| Rick Carron | Superior Plus Corp | N/A | |
| JeanJacques Henchoz | Talanx AG | 59 | |
| Harry Kanwar | Superior Plus Corp | N/A | |
| Edgar Puls | Talanx AG | 50 | |
| Edward Kirnbauer | Identiv | 58 | |
Management Performance
| Return On Equity | -1.88 | |||
| Return On Asset | 0.0338 |
Bausch Health Companies Leadership Team
Elected by the shareholders, the Bausch Health's board of directors comprises two types of representatives: Bausch Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bausch. The board's role is to monitor Bausch Health's management team and ensure that shareholders' interests are well served. Bausch Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bausch Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeff Hartness, Commercial Access | ||
| Kathleen Fitzpatrick, VP Officer | ||
| John Barresi, Controller VP | ||
| Arthur Shannon, IR Contact Officer | ||
| Seana Carson, Exec Counsel | ||
| Tage MD, Chief RD | ||
| Robert Butz, VP Affairs | ||
| Thomas Appio, Executive Vice President and Presidentident - Asia Pacific | ||
| Thomas Vadaketh, Ex CFO | ||
| Mirza Dautbegovic, VP COO |
Bausch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bausch Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.88 | |||
| Return On Asset | 0.0338 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 22.26 B | |||
| Shares Outstanding | 361.87 M | |||
| Shares Owned By Insiders | 3.27 % | |||
| Shares Owned By Institutions | 81.80 % | |||
| Price To Earning | 3.37 X | |||
| Price To Book | 18.34 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Bausch Stock
When determining whether Bausch Health Companies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bausch Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bausch Health Companies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bausch Health Companies Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bausch Health Companies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.